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Structured summary  
Aim: Evaluating the public health impact of regulatory interventions is important 
but there is currently no common methodological approach to guide this 
evaluation. This systematic review provides a descriptive overview of the 
analytical methods for impact research.  
Methods: We searched MEDLINE and EMBASE for articles with an empirical 
analysis evaluating the impact of European Union or non-European Union 
regulatory actions to safeguard public health published until March 2017. 
References from systematic reviews and articles from other known sources were 
added. Regulatory interventions, data sources, outcomes of interest, 
methodology and key findings were extracted. 
Results: From 1,246 screened articles, 229 were eligible for full-text review and 
153 articles in English language were included in the descriptive analysis. Over a 
third of articles studied analgesics and antidepressants. Interventions most 
frequently evaluated are regulatory safety communications (28.8%), black box 
warnings (23.5%) and direct healthcare professional communications (10.5%).  
55% of studies measured changes in drug utilisation patterns, 27% evaluated 
health outcomes and 18% targeted knowledge, behaviour, or changes in clinical 
practice. Unintended consequences like switching therapies or spill-over effects 
were rarely evaluated. Two thirds used before-after time series and 15.7% 
before-after cross-sectional study designs. Various analytical approaches were 
applied including interrupted time series regression (31.4%), simple descriptive 
analysis (28.8%) and descriptive analysis with significance tests (23.5%). 
Conclusion: Whilst impact evaluation of pharmacovigilance and product-specific 
regulatory interventions is increasing, the marked heterogeneity in study 
conduct and reporting highlights the need for scientific guidance to ensure 
robust methodologies are applied and systematic dissemination of results occurs.  
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Introduction 
Prescribing medicines is the most common health intervention globally and the 
safe use of medicines is paramount to public health. An estimated 3.5% of 
hospitalisations in Europe are caused by adverse drug reactions (ADRs), and up 
to 10% of hospitalised patients experience an ADR during their hospital stay [1].  
To minimise the risks from medicines, pharmacovigilance systems have been 
established to continuously monitor their safety. These regulatory systems are 
designed to detect changes in the benefit-risk balance of a medicine which only 
become apparent during routine clinical use. Once safety signals have been 
evaluated and confirmed, appropriate regulatory action is taken to minimise the 
risks, such as labelling change, restriction, contraindication or withdrawal of a 
product or class of products.  
Pharmacovigilance activities include monitoring of the effectiveness of risk 
minimisation measures. The European Union (EU) pharmacovigilance legislation 
aimed to strengthen these activities and was found to lead to faster changes to 
product labelling and the conclusion of safety referrals [2]. However, despite the 
potential for large global public health consequences, there is limited evidence 
about the effectiveness and consequences of regulatory actions at the population 
level, particularly relating to public health outcomes. To address this knowledge 
gap, the European Medicines Agency’s Pharmacovigilance Risk Assessment 
Committee (PRAC) adopted in 2016 a strategy [3] aiming to assess whether 
pharmacovigilance activities achieve their intended objectives and to identify 
areas where performance could be enhanced [4]. 
In order to achieve their desired effect, regulatory interventions are expected to 
lead to changes in knowledge, attitudes and healthcare practices of individuals 
(i.e. patients, consumers, and healthcare professionals) and organisations. Yet 
the possibility of unintended consequences remains if measures are not properly 
implemented which may give raise to criticism.  
Measuring the impact of pharmacovigilance interventions is challenging as 
treatment and disease outcomes often overlap, and there may be significant 
time lags until clinical effects are seen with many existing studies being 
ecological in nature. It can also be difficult to evaluate decisions relating to 
single products if use is low and potential clinical outcomes are rare or when 
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multiple interventions occur simultaneously. Nearly 50 years after the creation of 
the first national programmes for pharmacovigilance [5] there are no established 
guidelines for measuring the impact of regulatory interventions on public health 
[6-8]. 
Studies evaluating the effectiveness of risk minimisation interventions often rely 
on surrogate measures such as changes in behaviour or prescribing rather than 
actual health outcomes [9]. For example, measuring drug usage in population-
based electronic health records as a surrogate for changes in morbidity or 
mortality was one of various methods recommended at an international 
workshop exploring methodologies for measuring the impact of 
pharmacovigilance activities [10]. Heterogeneity in study design and method of 
analysis also mean that proper interpretation and comparisons between 
regulatory systems are difficult.   
We performed a systematic review of studies measuring the impact of 
pharmacovigilance regulatory interventions worldwide to highlight their 
methodological challenges and inform the conduct and reporting of future 
studies. 
Methods 
Literature screening  
A protocol for a systematic search strategy was constructed a-priori to identify 
articles evaluating the impact of regulatory interventions on healthcare 
utilisation, health knowledge and behaviour, or health outcomes. The search was 
performed in MEDLINE and EMBASE using Medical Subject Heading (MeSH) 
terms and keywords related to impact research in pharmacovigilance, regulatory 
policy, health outcome research, risk assessment, effectiveness of risk 
minimisation, health behaviour and health outcomes. The database search was 
supplemented with hand searching of references from systematic reviews, 
including articles and other known in-house sources (‘snowballing’). The protocol 
is available in the public European Union electronic Register of Post-
Authorisation Studies (EU PAS Register®)1 under study number EUPAS21337.  
                                                     
1 http://www.encepp.eu/encepp_studies/indexRegister.shtml. 
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Study selection 
Eligible articles were initially screened by title and abstract by one of three 
reviewers with experience in regulatory science and pharmacoepidemiology (TG, 
DM, AP) (Figure 1). In a second stage, the eligibility of articles was 
independently evaluated after full text review and, where disagreement was 
present, discussions between the three reviewers were held to reach consensus. 
Inclusion and exclusion criteria 
Articles in English language published up to 31 March 2017 evaluating regulatory 
interventions for medicines for human use were included. Duplicates, abstracts, 
letters to editors, commentaries and articles analysing the impact health policy 
changes and studies investigating the impact of pharmacovigilance processes 
were excluded. We defined a regulatory intervention as any regulatory action 
taken by an EU or non-EU competent authority to safeguard public health in 
relation to the use of medicinal products, including label changes, risk 
communication to the public or healthcare providers, product-specific additional 
risk minimisation measures defined in Good Pharmacovigilance Practices (GVP) 
module XVI [11], withdrawal or suspension of a marketing authorisation.  
Data extraction and analysis 
A standardised data extraction form was applied to obtain the following 
information: publication title, year, regulatory intervention and date/period, data 
source, study design, country, analytical method, outcome measure, and drug 
therapeutic class (ATC code). In addition, key findings, conclusions and any 
limitations of the studies were captured to support the review process. Data 
extraction was performed separately by each reviewer.  
To synthesise information on the methodology for impact measurement of the 
studies identified, we categorised studies into one of the following mutually 
exclusive groups based on study design and analytical approach: before-after 
time series (defined as an evaluation at three or more time points crossing the 
date of the regulatory intervention), before-after cross-sectional study (defined 
as an evaluation at one point in time before and after the date of the regulatory 
intervention), single time point cross-sectional study (defined by a single time 
point after the date of the regulatory intervention), cohort study, and 
randomised controlled trial.  
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Categorisation of included variables 
For descriptive purposes we defined seven categories of regulatory 
interventions: direct healthcare professional communication (DHPC), black box 
warning, product information update, regulatory safety communication (e.g., 
guideline update, public health advisory communication, safety communication 
on websites), other additional risk minimisation measures (e.g. medication 
guide, pregnancy prevention programme, controlled distribution), product 
suspension/withdrawal, and others (e.g. change in legal status, pack-size 
restriction). 
Analytical approaches for each study design were categorised as follows: 
descriptive analysis (with or without statistical significance tests), regression 
based approaches as described in the literature including Poisson and logistic 
regression [12], interrupted time series (ITS) regression [13], Joinpoint 
regression [14] and others.   
Outcome measures were categorised into three groups: i) drug utilisation, ii) 
health outcomes and iii) knowledge, behaviour and clinical practice. A descriptive 
analysis of included studies was undertaken based on the extracted study 
information.  
Results 
The systematic review identified 1,246 articles of which 229 were eligible for full-
text review, and 153 articles met the inclusion criteria and were retained in the 
descriptive analysis (Figure 1).  
Overview of studies 
Out of 153 studies included in our analysis, 70 (45.8%) assessed the impact of 
regulatory interventions in the United States (US), 69 (45.0%) in Europe and 14 
(9.2%) in the rest of the world. Analgesics and antidepressants were the most 
common therapeutic classes, each being evaluated in 27 (17.6%) studies, 
followed by blood glucose lowering drugs with 14 (9.2%), antipsychotics with 13 
(8.5%) studies, and retinoids for systemic use with 12 (7.8%) studies (Table 1). 
The most frequently evaluated single regulatory interventions related to the risk 
associated with paracetamol poisoning and overdose, the risk of suicide in 
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children and adolescents treated with serotonin reuptake inhibitors (SSRIs) and 
the cardiovascular risks with thiazolidinediones.  
The most commonly evaluated regulatory interventions included regulatory 
safety communications (28.8%) and black box warnings (23.5%, US only). A 
quarter of studies evaluated DHPCs (10.5%) and other additional risk 
minimisation measures (15.7%), including pregnancy prevention programmes. 
About 13% of studies evaluated the impact of pack-size restrictions. Product 
withdrawals and individual product information updates were least frequently 
assessed (7.2% and 1.3% respectively). Seventy-three studies (47.7%) 
evaluated the impact of a single regulatory intervention whereas 80 studies 
(52.3%) looked at the impact of multiple interventions occurring simultaneously 
or over time.  
Studied outcomes 
Eighty-four studies (54.9%) measured drug utilisation patterns and only 42 
studies (27.5%) evaluated health outcomes such as morbidity (e.g. reduction of 
disease or adverse reaction incidence), mortality (e.g. reduction in suicide 
rates), pregnancy related outcomes or changes in laboratory values as surrogate 
measure for health improvements as shown in Table 2. Among studies which 
evaluated health outcomes, a positive impact of the regulatory intervention was 
reported in 27 (64%) studies whereas 12 (29%) studies showed no or negligible 
effects and in 3 (7%) studies the results were inconclusive.   
Twenty-seven (17.6%) studies evaluated changes in patients’ or healthcare 
professionals’ knowledge and behaviour, or changes in clinical practice targeted 
by the regulatory intervention. Only a small number of studies examined 
unintended consequences of regulatory interventions such as switching of 
therapies or ‘spill-over’ effects (e.g. decrease of drug use in sub-populations not 
targeted by the regulatory action).  
Study design, methodology and data sources  
Over 80% of studies used a before-after design with 101 (66.0%) before-after 
time series analyses and 24 (15.7%) before-after cross-sectional studies (Table 
3). There was only one randomized controlled trial identified designed to 
evaluate the impact of interventions, and six cohort studies. Seven different 
analytical approaches were identified. The most commonly used analytical 
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approach was ITS regression in 48 (31.4%) studies, with simple descriptive 
analysis in 44 (28.8%) and descriptive analysis with statistical significance tests 
in 36 (23.5%) studies as shown in Table 3.  
Administrative claims databases and electronic health record databases where 
the main data sources used to measure impact (Figure 2). Among the research 
conducted in the US, claims databases dominated the picture, being used in 
26.1% of studies whereas in Europe claims databases and electronic healthcare 
records were used in similar proportions (13.7% and 15%). Other types of data 
sources relevant for impact research were questionnaires, medical charts, 
national registers (e.g. on birth, mortality, poisoning), national surveillance 
systems (e.g. US Sentinel), national patient safety incident reporting systems or 
electronic prescribing systems.  Figure 3 shows how study designs and analytical 
methods evolved over time with a significant trend of increasing use of ITS 
regression analysis (p=0.003).  
Discussion 
Our systematic review aimed to describe studies measuring the impact of 
regulatory interventions with a focus on study designs, analytical methods, data 
sources and choice of outcome measures. We found a marked heterogeneity in 
published studies of regulatory interventions with variation by region, study 
design, analytical approach and main outcomes evaluated.  
The published studies evaluated regulatory interventions in Europe and the US in 
similar proportions, and both regions together accounted for the majority of the 
global literature in English language, potentially affecting the generalisability of 
results to other populations. This is also the case for studies conducted in the EU 
where the organisation of healthcare systems varies markedly between countries 
and may affect results of impact research. An element of this variation may be 
the availability of large electronic data sources in some countries only where 
impact studies are feasible.  
Although the number of identified studies was relatively large, the range of 
therapeutic classes subject to impact research was limited with several studies 
evaluating the same regulatory intervention (e.g. suicidality with SSRIs in 
paediatric patients, mortality risk of dementia patients treated with 
antipsychotics, cardiovascular risks with thiazolidinediones, mortality associated 
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with paracetamol poisoning and overdose) (Table 3). The latter is an early 
example of impact research evaluating the effects of legislation which reduced 
the maximum pack size of paracetamol containing medicines in the United 
Kingdom in 1998. Despite an apparent decrease in paracetamol-associated 
mortality rates and hospital admissions the public health impact of these 
observed changes remained unclear. The decline in mortality and hospital 
admissions had begun before the legislation and the variety of outcome 
measures and analytical approaches used made it difficult to determine whether 
or not the legislation has been a success [168].  
Some articles focused on regulatory actions suggesting uncertain effects in 
several countries or that require adjustments in their implementation, as shown 
for isotretinoin pregnancy prevention programmes in Europe [169]. It is unclear 
why only certain regulatory interventions have been evaluated. The choice of 
regulatory interventions evaluated might be driven by the higher public health 
importance (e.g. unintended pregnancy with teratogenic medicines), by the 
feasibility of studies using available data sources (e.g. availability of pharmacy 
dispensed prescribing data versus chemotherapy or biological agents) and by 
funding opportunities. To help assess the need for such studies, the PRAC has 
developed criteria for prioritising impact research in areas where there is a need 
to generate additional data to monitor the impact of regulatory interventions 
which are based on three pillars: the public health importance of the regulatory 
action, the potential impact on clinical practice and whether the study will deliver 
decision relevant data [170]. 
The vast majority of studies included in our review were drug utilisation studies 
and relatively few evaluated clinical outcomes. Whilst drug utilisation provides 
proxy measures of impact, it is uncertain whether the changes in drug use 
translate into discernible clinical or public health benefits. In this regard, the 
actual consequences of changes in drug usage are often unknown or unintended 
consequences may occur. For example, research conducted in the US and the 
Netherlands showed a decrease in SSRI prescriptions for children and 
adolescents after US and European warnings in 2003 about a suicide risk with 
antidepressant use in this age group. However, this decrease in use seemed to 
be associated with an unintended increase in suicide rates in children and 
adolescents due to untreated patients [27]. In the same context, time-series 
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analyses of antidepressant prescribing in adults showed statistically and clinically 
significant spill-over effects associated with the 2003 Food and Drug 
Administation (FDA) public health advisory on antidepressant use in paediatric 
patients [44]. In addition, the impact of pharmacovigilance on health outcomes 
is often more difficult to measure due to a lack of adequate data sources and the 
difficulty of proving a causal association between the observed changes and the 
regulatory intervention, particularly at product level.  
The choice of study design and analytical approach varied. Guidelines describing 
the optimal study design and analytical approaches for evaluating the impact of 
pharmacovigilance are lacking. Whilst each situation may differ, studies 
estimating the net attributable impact of regulatory interventions require 
considering the target drug, clinical outcomes and the potential for switching 
therapies and unintended consequences. Few studies took into account possible 
unintended consequences, such as the effect in groups not targeted by the 
intervention through age or disease risk, or measuring therapeutic alternatives 
that may be used as substitutes [131; 133].  
Uncontrolled before-after cross-sectional studies were used in 15.7% of studies 
and evaluated periods of time immediately before and after a regulatory 
intervention most commonly applying simple descriptive statistics (such as t-test 
or chi-square test) to determine if changes were significant. Although this design 
requires less data collection, pre-intervention trends are ignored potentially 
leading to overestimate the effect of the intervention. Such tests also assume 
that data points are independent, which is often an incorrect assumption. 
Before-after time series was the most widely used study design to measure the 
impact of regulatory interventions. However, only 65 (42.5%) studies used 
statistical regression-based approaches to determine significance. Although 
studies without regression modelling may be suitable for large immediate 
changes (e.g. product withdrawals) they risk producing spurious results when 
assessment is more subjective. ITS regression is a robust quasi-experimental 
design to evaluate longitudinal effects of time-delimited interventions. 
Segmented regression analysis of interrupted time series data can be used to 
quantify the immediate change in outcome following an intervention, and 
changes in trend [171]. However, ITS regression requires the date of the 
regulatory intervention to be pre-specified which can be difficult to define, 
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particularly when implementation varies, and that autocorrelation is assessed. 
Furthermore, adequate power to conduct ITS regression requires sufficient data 
points as with all time-series approaches, and changes may be influenced by 
other interventions occurring during the same time frame (e.g. media coverage). 
However, in most instances, these data were not fully reported.  
In contrast, Joinpoint regression models plot trends lines at points where 
changes in prescribing or the incidence of an outcome have occurred. A potential 
advantage of such models is that intervention date does not need to be pre-
specified offering potential advantages if the implementation date varies or is 
unknown. All time series approaches measure associations rather than causation 
and due to the ecological nature of the study design are even more challenging 
to be applied to public health outcomes. 
Approximately a third of the studies employed descriptive statistics providing 
only weak evidence to support a causal association, which in many cases will be 
considered inadequate. 
Limitations 
Not all impact research may have been published in scientific journals and a vast 
majority of studies is communicated within regulatory procedures but seldom 
published. Unpublished research was not captured by our search strategy and 
therefore not included in the review. There is also a risk of publication bias, 
reflected by the higher percentage of published articles which reported positive 
outcomes. Some articles might have been missed due to a lack of common 
definitions and consistent terminology to describe such studies. A previous 
review of the use of ITS methods in drug utilisation research showed a large 
variation in the reporting of analytic methods [172], confirming our findings and 
the need for standardised reporting. Therefore, our search strategy was 
supplemented with references from published review articles and known in-
house literature. Although different study designs and analytical methods are 
described, there has been no assessment of the risk of bias and of the quality 
which requires further review. The challenge of evaluating multiple coinciding 
interventions remains to be addressed and the effectiveness of individual 
regulatory measures may not be discernible other than by interventional study 
designs. 
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Conclusion 
Despite their potential global impact, the effects of pharmacovigilance regulatory 
interventions remain largely unquantified. A collaborative effort is required 
among regulators, health technology assessment bodies, academia, and industry 
to help define measurable public health outcomes including intended and 
unintended consequences of regulatory decisions at the population level. 
Guidelines on the reporting of such studies and research to establish the best 
methods to evaluate such interventions are required. Results of impact research 
should be systematically disseminated to increase knowledge on the 
effectiveness of regulatory interventions. The EU PAS Register®, a publicly 
accessible platform for observational post-authorisation research, could be used 
for this purpose. 
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Table 1: Proportion of impact research articles (n=153) by anatomical therapeutic 
chemical (ATC) classes and geographic regions (left). The right side shows the evaluated 
regulatory intervention(s). 
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Analgesics 27 (17.6) 1 - 1 4 3 4 18 
Europe 24 (15.7) - - 1 3 2 4 18 
United States 3 (2.0) 1 - - 1 1 - - 
Rest of the World - - - - - - - - 
Antidepressants 27 (17.6) 1 17 7 22 2 - - 
Europe 8 (5.2) 1   3 6 - - - 
United States 15 (9.8)  - 14 3 13 1 - - 
Rest of the World 4 (2.6) 0 3 1 3 1 - - 
Blood glucose lowering drugs1  14 (9.2) 4 5 8 7 - 2 - 
Europe 5 (3.3) 2  - 4 3   2   
United States 8 (5.2) 2 5 3 3 - - - 
Rest of the World 1 (0.7) -  -  1 1 - - - 
Antipsychotics 13 (8.5) 3 5 3 7 - - - 
Europe 5 (3.3)  - -  1 5 - - - 
United States 7 (4.6) 2 5 2 1 - - - 
Rest of the World 1 (0.7) 1 -   - 1 - - - 
Retinoids for systemic use 12 (7.8) - - 1 - 11 - 1 
Europe 7 (4.6) - - 1 - 6 - 1 
United States 3 (2.0)  - -   -  - 3 -  -  
Rest of the World 2 (1.3)  - -  -  -  2 -  -  
Hormonal contraceptives 5 (3.3) - 3 - 2 - - - 
Europe 2 (1.3) - - - 2 - - - 
United States 3 (2.0) - 3 - - - - - 
Rest of the World - - - - - - - - 
NSAIDs2  5 (3.3) - - 2 4 1 3 - 
Europe 5 (3.3) - - 2 4 1 3 - 
United States - - - - - - - - 
Rest of the World - - - - - - - - 
Propulsives3  5 (3.3) 4 1 3 - 1 - - 
Europe - - - - - - - - 
United States 5 (3.3) 4 1 3 - 1 - - 
Rest of the World - - - - - - - - 
Antihistamines  4 (2.6) 2 4 - - - - - 
Europe - - - - - - - - 
United States 4 (2.6) 2 4 - - - - - 
Rest of the World - - - - - - - - 
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Cough and cold preparations 4 (2.6) - - 2 2 - 2 - 
Europe - - - - - - - - 
United States 4 (2.6) - - 2 2 - 2 - 
Rest of the World - - - - - - - - 
Hormone replacement therapy 4 (2.6) - - 1 4 - - - 
Europe 4 (2.6) - - 1 4 - - - 
United States - - - - - - - - 
Rest of the World - - - - - - - - 
Antiasthmatics 3 (2.0) 1 1 3 2 1 - - 
Europe -  -  -  -  -  -  - -  
United States 3 (2.0) 1 1 3 2 1    - 
Rest of the World -  -  -  -  -  -  -  - 
Psychostimulants4  3 (2.0) - 3 2 2 1 - - 
Europe - - - - - - - - 
United States 3 (2.0) - 3 2 2 1 - - 
Rest of the World - - - - - - - - 
Other drugs5  27 (17.6) 6 5 7 12 6 - 1 
Europe 9 (5.9) 3 - 1 7 2 - - 
United States 12 (7.8) 1 5 2 4 2 - 1 
Rest of the World 6 (3.9) 2 - 4 1 2 - - 
Total 153 (100) 22 44 40 68 26 11 20 
 
1 Thiazolidinediones 
2 Nonsteroidal anti-inflammatory drug 
3 Cisapride 
4 Agents used for attention deficit hyperactivity disorder (ADHD) 
5 Therapeutic classes with less than three studies identified were grouped together. 
6 Dear Health Care Professional Communication 
7 Other regulatory interventions include studies evaluating the impact of paracetamol pack size restrictions, the 
impact of a healthcare reminder system for patient monitoring, the impact of advice on the clinical 
management of drug poisoning and compliance with national guidelines for isotretinoin. 
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Table 2: Distribution of outcome measures evaluated in regulatory impact research 
(n=153 articles). 
 
Outcome measure  Articles N (%) References 
Drug utilisation 84 (54.9)  
Health outcomes 42 (27.5)  
Mortality 20 (13.1)  
-Drug poisoning/overdose 12 (7.8) [15-26]  
-Suicide and self-harm 7 (4.6) [27-33]  
-Other 1 (0.7) [34] 
Hospitalisation* 9 (5.9) [35-43]  
Risk incidence# 6 (3.9) [44-49]  
Pregnancy related outcomes^ 3 (2.0) [50-52]  
Adverse drug reaction(s) reporting 2 (1.3) [53-54]  
Laboratory tests‡ 2 (1.3) [55-56] 
Knowledge, behaviour or clinical practice 27 (17.6)  
*Hospital admission due to myocardial infarction, cancer, hip fracture, drug poisoning or overdose, pulmonary 
embolism, drug-induced liver injury, child unsupervised ingestion; 
#Venous thromboembolism; breast cancer; opioid abuse, addiction or overdose; stroke; osteonecrosis of the 
jaw; depression;  
^Unplanned pregnancy, spontaneous or medically induced abortion, birth defect;  
‡Serum glucose and lipid testing; change in mean HbA1c and fasting plasma glucose levels; 
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Table 3: Overview of study designs and analytical approaches of the final list of articles 
(n=153).  
Design and analytical method  Articles N (%) References 
Before/after time series  101 (66.0)  
Descriptive analysis only 21 (13.7) [17; 24; 26; 49; 54-55; 57-71]  
Descriptive statistics with significance test 12 (7.8) [19; 23; 50; 53; 72-79]  
Interrupted time series regression 48 (31.4) [22; 29-30; 31; 38; 44; 56; 80-120]  
Joinpoint regression 9 (5.9) [28; 37; 39; 121-126]  
Poisson regression 5 (3.3) [18; 27; 32; 34; 46]  
Logistic regression 3 (2.0) [48; 127-128]  
Other 3 (2.0) [21; 129-130]  
Before/after cross-sectional study                                                                          24 (15.7)
Descriptive analysis only 4 (2.6) [41-42; 45; 131]  
Descriptive statistics with significance test 18 (11.8) [15-16; 25; 33; 35-36; 40; 43; 47; 
132-140]  
Poisson regression  1 (0.7) [20] 
Logistic regression 1 (0.7) [141] 
Single time point cross-sectional study 21 (13.7)  
Descriptive analysis only 16 (10.5) [142-157] 
Descriptive statistics with significance test 4 (2.6) [158-161] 
Other 1 (0.7) [162] 
Cohort study  6 (3.9)  
Descriptive analysis only 3 (2.0) [52; 163-164] 
Descriptive statistics with significance test 2 (1.3) [51; 165] 
Other 1 (0.7) [166] 
Randomised controlled trial (RCT) 1 (0.7)  
Logistic regression 1 (0.7) [167] 
 
 
  
Methods for Measuring Impact of Medicines Regulatory Interventions  
This article is protected by copyright. All rights reserved. 
 
 
Figure 1: Literature search and systematic review strategy.  
#Known literature and relevant references of published systematic reviews were included. 
*Duplicates, abstracts, letters to editors, commentaries and articles analysing the impact of other 
interventions (i.e. process and health policy related) were excluded.  
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Figure 2: Types of data sources used for regulatory impact research (n=153 
articles). 
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Figure 3: Distribution of study designs (A) and analytical methods (B) in impact 
research over time (n=153). 
*Includes randomised clinical trials and cohort studies. 
#p=0.003 using chi-squared test for trend. 
 
 
